Sanofi Extends Takeover Bid for Blueprint Medicines to July 17
PorAinvest
jueves, 17 de julio de 2025, 2:42 am ET1 min de lectura
BPMC--
As of the close of business on July 16, 2025, approximately 29,742,419 shares, representing 45.85% of the total outstanding shares of Blueprint, have been validly tendered. Additionally, 23,400,152 shares have been tendered by notice of guaranteed delivery, representing approximately 36.08% of the outstanding shares. These shares are not deemed validly tendered until they are delivered to the depositary prior to the offer's expiration.
The tender offer price stands at $129 per share, with an additional non-transferable contractual right per share. This right represents the potential for contingent payments of up to $6.00 per share upon the achievement of specified milestones.
The extension of the offer is subject to certain conditions, including the tender of a majority of the outstanding shares of Blueprint’s common stock. The offer is being made pursuant to the terms and conditions described in the offer to purchase, dated June 17, 2025, as amended. Holders of shares who have already tendered their shares do not need to re-tender or take any further action.
For more information, shareholders can contact Innisfree M&A Incorporated at +1 877 750-0831 or +1 212 750-5833.
[1] https://finance.yahoo.com/news/press-release-sanofi-announces-extension-050000353.html
SNY--
Sanofi extends its takeover bid for Blueprint Medicines by one day, with the new expiry date set for 5:00 p.m. EDST on 17 July. As of now, 29,742,419 shares (45.85% of the total outstanding shares) have been validly tendered and 23,400,152 shares have been tendered by guaranteed delivery notice. The tender offer price is $129 per share, plus a contingent non-transferable contractual right per share.
Sanofi has extended its takeover bid for Blueprint Medicines Corporation by one day, with the new expiry date set for 5:00 p.m. EDST on July 17, 2025. The initial tender offer, which was scheduled to expire at 12:01 a.m. EDST on July 17, 2025, has been extended to allow more time for shareholders to tender their shares.As of the close of business on July 16, 2025, approximately 29,742,419 shares, representing 45.85% of the total outstanding shares of Blueprint, have been validly tendered. Additionally, 23,400,152 shares have been tendered by notice of guaranteed delivery, representing approximately 36.08% of the outstanding shares. These shares are not deemed validly tendered until they are delivered to the depositary prior to the offer's expiration.
The tender offer price stands at $129 per share, with an additional non-transferable contractual right per share. This right represents the potential for contingent payments of up to $6.00 per share upon the achievement of specified milestones.
The extension of the offer is subject to certain conditions, including the tender of a majority of the outstanding shares of Blueprint’s common stock. The offer is being made pursuant to the terms and conditions described in the offer to purchase, dated June 17, 2025, as amended. Holders of shares who have already tendered their shares do not need to re-tender or take any further action.
For more information, shareholders can contact Innisfree M&A Incorporated at +1 877 750-0831 or +1 212 750-5833.
[1] https://finance.yahoo.com/news/press-release-sanofi-announces-extension-050000353.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios